FIRST WAVE BIOPHARMA (FWBI) Stock Analyst Earnings Estimates
NASDAQ:FWBI - Nasdaq - US33749P4081 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 178.96% | N/A 90.20% | |||||||||||
| EBITDA YoY % growth | -1.9M | -4M -110.53% | -5.6M -40.00% | -9.47M -69.11% | -12.63M -33.37% | -13.72M -8.63% | -25.86M -88.48% | -56.17M -117.21% | -12.65M 77.48% | -15.742M -24.44% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.33M | -4.73M -103.00% | -6.33M -33.83% | -10.22M -61.45% | -13.43M -31.41% | -14.74M -9.75% | -26.43M -79.31% | -56.71M -114.57% | -12.68M 77.64% | -15.771M -24.38% | N/A -37.50% | N/A -47.77% | N/A -67.33% | N/A -11.46% | N/A 125.27% | N/A 740.32% | N/A 118.36% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -315.00 95.01% | -270.00 14.29% | -218.53 19.06% | -255.00 -16.69% | -1,248.15 -389.47% | -362.30 70.97% | -88.75 75.50% | N/A 95.87% | N/A 56.88% | N/A -45.16% | N/A 3.11% | N/A 121.10% | N/A 628.26% | N/A 50.75% |
All data in USD
| Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -2.48 93.19% | -0.33 99.14% | -0.80 91.30% | -0.73 86.37% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.218M -3.88% | -4.858M -16.23% | -5.738M -67.27% | -6.871M -67.84% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2023 Q2Q % growth | -5.35 97.18% | -4.12 | -1.23 | -29.99% |
| Q3 2023 Q2Q % growth | -9.20 -150.55% | -12.55 | 3.35 | 26.67% |
| Q2 2023 Q2Q % growth | -37.80 28.00% | -21.22 | -16.58 | -78.17% |
| Q1 2023 Q2Q % growth | -36.40 73.74% | -43.45 | 7.05 | 16.23% |
| Q4 2022 Q2Q % growth | -189.40 -3.24% | -59.26 | -130.14 | -219.60% |
| Q3 2022 Q2Q % growth | 18.20 102.65% | -21.49 | 39.69 | 184.69% |
| Q2 2022 Q2Q % growth | -52.50 84.38% | -136.02 | 83.52 | 61.40% |
| Q1 2022 Q2Q % growth | -138.60 -230.00% | -113.53 | -25.07 | -22.09% |
| Q4 2021 Q2Q % growth | -183.45 -97.26% | -162.08 | -21.38 | -13.19% |
| Q3 2021 Q2Q % growth | -686.70 -1,246.47% | -171.36 | -515.34 | -300.74% |
| Q2 2021 Q2Q % growth | -336.00 -558.82% | -155.30 | -180.70 | -116.36% |
| Q1 2021 Q2Q % growth | -42.00 30.00% | -22.19 | -19.82 | -89.32% |
| Q4 2020 Q2Q % growth | -93.00 -539.97% | -41.62 | -51.38 | -123.47% |
| Q3 2020 Q2Q % growth | -51.00 | -41.62 | -9.38 | -22.55% |
| Q2 2020 Q2Q % growth | -51.00 32.00% | -32.44 | -18.56 | -57.23% |
| Q1 2020 Q2Q % growth | -60.00 23.08% | -35.96 | -24.05 | -66.88% |
| Q4 2019 Q2Q % growth | -14.53 | -48.96 | 34.43 | 70.32% |
| Q3 2019 Q2Q % growth | -51.00 | -48.20 | -2.80 | -5.82% |
| Q2 2019 Q2Q % growth | -75.00 | -65.79 | -9.21 | -14.00% |
| Q1 2019 Q2Q % growth | -78.00 | -54.06 | -23.94 | -44.28% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -0.62% | -6.81% | 0% | 32.61% |
| Revenue | N/A | N/A | N/A | N/A |